Literature DB >> 20463862

Thrombolytic Treatment After Acute Ischemic Stroke Results from the Minnesota Stroke Registry and Opportunities to Improve Care.

Kamakshi Lakshminarayan1, James M Peacock, Russell V Luepker, Albert W Tsai.   

Abstract

BACKGROUND: We used data from the Minnesota Stroke Registry to examine rates of intravenous thrombolytic therapy in acute ischemic stroke and identifed opportunities to improve the utilization of this treatment.
METHODS: We analyzed a total of 1010 acute ischemic stroke patients who had been entered into the registry by 13 participating hospitals during the first three quarters of the 2008 calendar year.
RESULTS: Of the 1010 patients only 121 (12%) came within 2 hours of symptom onset. Intravenous recombinant tissue plasminogen activator (rt-PA) was administered to 32/55 (58%) of the patients who arrived within 2 hours of symptom onset and met eligibility criteria for this treatment. The remaining 66 patients had a documented reason for non-treatment. The most common reason (22/66) for non-treatment was rapid resolution of symptoms or mild stroke. Out of those 22 patients, 20 were ambulating independently prior to admission and only 9/20 (45%) ambulated independently at discharge.
CONCLUSION: Further community education on the need for immediate medical attention after stroke is needed. Patients appropriately excluded from rt-PA treatment due to mild deficits or rapidly improving symptoms seem to have poor discharge outcomes. This subgroup of patients will have to be studied further, preferably in the context of a clinical trial.

Entities:  

Year:  2008        PMID: 20463862      PMCID: PMC2867615     

Source DB:  PubMed          Journal:  J Vasc Interv Neurol        ISSN: 1941-5893


  5 in total

1.  Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility.

Authors:  P A Barber; J Zhang; A M Demchuk; M D Hill; A M Buchan
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

2.  One-year follow-Up in acute stroke patients treated with rtPA in clinical routine.

Authors:  S Schmülling; M Grond; J Rudolf; W D Heiss
Journal:  Stroke       Date:  2000-07       Impact factor: 7.914

3.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

4.  Administration of tissue plasminogen activator for acute ischemic stroke in a rural Wisconsin hospital.

Authors:  Ron Charipar; Elizabeth Charipar
Journal:  WMJ       Date:  2008-07

5.  Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.

Authors:  Harold P Adams; Gregory del Zoppo; Mark J Alberts; Deepak L Bhatt; Lawrence Brass; Anthony Furlan; Robert L Grubb; Randall T Higashida; Edward C Jauch; Chelsea Kidwell; Patrick D Lyden; Lewis B Morgenstern; Adnan I Qureshi; Robert H Rosenwasser; Phillip A Scott; Eelco F M Wijdicks
Journal:  Circulation       Date:  2007-05-22       Impact factor: 29.690

  5 in total
  1 in total

1.  Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment.

Authors:  Wondwossen G Tekle; Saqib A Chaudhry; Zara Fatima; Maryam Ahmed; Shujaat Khalil; Ameer E Hassan; Gustavo J Rodriguez; Fareed K Suri; Adnan I Qureshi
Journal:  J Vasc Interv Neurol       Date:  2012-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.